The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by fostering Phase I and II clinical evaluations of promising new agents, biologic approaches, and routes of administration in the treatment of primary malignancies of the central nervous system (CNS) through the establishment of the CNS consortium titled """"""""New Approaches to Brain Tumor Therapy (NABTT)."""""""" This consortium is specifically designed to combine and focus the experience, resources, and capabilities of seven outstanding medical institutions (The Johns Hopkins University, Brown University, Columbia University, The Cleveland Clinic, The Massachusetts General Hospital, Northwestern University [Chicago], and The University of Pennsylvania) to bear on primary brain tumors. To meet this objective, the consortium will rely on the special strengths and abilities that rest within each participating institution and within the consortium as a whole. The participating institutions have (1) a large number of adult patients with primary brain tumors, (2) expert multidisciplinary clinical teams in place to care for these patients, (3) extensive clinical and laboratory resources, (4) a striking number of ongoing high quality, clinically relevant, peer-reviewed and NIH funded clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, Phase I and II clinical trials, neurosurgery, and neuropathology (6) extensive expertise in statistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these strengths by endorsed constitution, well-defined organizational structure, and emphasis on research design, protocol development, quality control, study monitoring, and data management and analysis. The secondary long-term objective of this proposal is to utilize this consortium to share human brain tumor specimens as well as other clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuropharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors. This objective will be reached using the strengths of the individual institutions and the NABTT CNS Consortium which are outlined above.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (68))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Blakeley, Jaishri O; Grossman, Stuart A; Chi, Andrew S et al. (2018) Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res :
Blakeley, Jaishri O; Grossman, Stuart A; Mikkelsen, Tom et al. (2015) Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. J Neurooncol 125:123-31
Rosenfeld, Myrna R; Ye, Xiaobu; Supko, Jeffrey G et al. (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359-68
Peereboom, David M; Ahluwalia, Manmeet S; Ye, Xiaobu et al. (2013) NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 15:490-6
Grossman, Stuart A; Ye, Xiaobu; Peereboom, David et al. (2012) Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol 14:511-7
Nabors, L Burt; Mikkelsen, Thomas; Hegi, Monika E et al. (2012) A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118:5601-7
Rudek, Michelle A; New, Pamela; Mikkelsen, Tom et al. (2011) Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol 105:375-81
Batchelor, T T; Grossman, S A; Mikkelsen, T et al. (2011) Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76:929-30
Nabors, L B; Supko, J G; Rosenfeld, M et al. (2011) Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 13:1324-30
Grossman, Stuart A; Ye, Xiaobu; Lesser, Glenn et al. (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473-80

Showing the most recent 10 out of 42 publications